The Dublin, Ireland-based company posted losses of $60.9 million, or 27¢ per share, on sales of $714.7 million for the three months ended June 30, seeing losses shrink 95.6% while sales shrunk 18.4% compared with the same period last year.
Adjusted to exclude one-time items, earnings per share were 76¢, well ahead of the 54¢ consensus on The Street, where analysts were looking for sales of $678.4 million, which the company also beat.
“Throughout 2018, we successfully executed on our strategic initiatives. We continued to reinvest into our specialty segment, which delivered record Xiaflex sales in the second-quarter. The recent growth of our U.S. Branded Sterile Injectables business has focused our efforts on completing the Somerset/Wintac acquisition, which remains on track to close in the fourth quarter. Additionally, we are proud to announce a new collaboration with Nevakar, Inc. We believe this collaboration will bring several critical care products to our sterile portfolio. Lastly, while our U.S. generic pharmaceuticals segment has faced a challenging market environment, we are cautiously optimistic that the portfolio decisions we made over the past 18 months position us well for the future,” prez & CEO Paul Campanelli said in a prepared statement.
The company lifted its financial guidance for the remaining year, now expecting to see sales of between $2.75 billion and $2.85 billion and adjusted EPS of between $2.50 and $2.60.
Shares in Endo have risen 18.5% so far today, at $14.99 as of 10:06 a.m. EDT.
In January, Endo was hit by a grand jury subpoena from the U.S. Attorney’s Office for the Southern District of Florida over its oxymorphone products.
These featured panels at DeviceTalks Boston will explore the state of R&D at major medtech firms, as well as the latest trends when it comes to developing combination products, neuromodulation devices, robotic systems and women's health technology.
View Technology Track Featured Sessions
Register today to save. Use code TECHTRACK to save an additional 10%.